Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis

Current Opinion in Investigational Drugs

Volumn 3, Issue 12, 2002, Pages 1720-1724

  Weydt, Patrick ^a   Weiss, Michael D ^a   Möller, Thomas ^a   Carter, Gregory T ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

ALS; Amyotrophic; Microglia; Neuro inflammation; Therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; CASPASE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GABAPENTIN; MINOCYCLINE; RILUZOLE; TACROLIMUS; TOPIRAMATE;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; MICROGLIA; MOTOR NEURON DISEASE; MOUSE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; RESPIRATORY FAILURE; REVIEW; SPASTICITY; SURVIVAL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; NEUROGENIC INFLAMMATION; SUPEROXIDE DISMUTASE;

EID: 0344838679     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Chancellor AM, Warlow CP: Adult onset motor neuron disease: Worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry (1992) 55(12):1106-1115.
2. Nelson S, Robinson I, Alperovitch A: Rising amyotrophic lateral sclerosis mortality in France 1968-1990: Increased life expectancy and inter-disease competition as an explanation. J Neurol (1994) 241(7):448-455.
3. Neilson S, Robinson I, Nymoen EH: Longitudinal analysis of amyotrophic lateral sclerosis mortality in Norway, 1966-1989: Evidence for a susceptible subpopulation. J Neurol Sci (1994) 122(2):148-154.
4. Wyss-Coray T, Mucke L: Inflammation in neurodegenerative disease - A double-edge sword. Neuron (2002) 35(3):419-432.
5. McGeer PL, McGeer EG: Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve (2002) 26(4):459-470.
6. McGeer PL, McGeer EG: Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging (2001) 22(6):799-809.
7. McGeer PL, McGeer EG: The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative disease. Brain Res Brain Res Rev (1995) 21(2):195-218.
8. Almer G, Guegan C, Teismann P, Naini A, Rosoklija G, Hays AP, Chen C, Przedborski S: Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol (2001) 49(2):176-185. This paper, along with [9], demonstrates a potential therapeutic target for cyclooxygenase-2 inhibitors in amyotrophic lateral sclerosis.
9. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL: Marked increase in cyclooxygenase-2 in ALS spinal cord: Implications for therapy. Neurology (2001) 57(6):952-956. This paper, along with [8], demonstrates a potential therapeutic target for cyclooxygenase-2 inhibitors in amyotrophic lateral sclerosis.
10. Tsuboi Y, Yamada T: Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (1994) 57(7):859-861.
11. Appel SH, Smith RG, Alexianu MF, Engelhardt JI, Stefani E: Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Adv Neurol (1995) 68:47-57.
12. Veldink JH, Van Den Berg LH, Cobben JM, Stulp RP, De Jong JM, Vogels OJ, Baas F, Wokke JH, Scheffer H: Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology (2001) 56(6):749-752.
13. Plaitakis A, Constantakakis E: Altered metabolism of excitatory amino acids, N-acetyl-aspartate-glutamate in amyotrophic lateral sclerosis. Brain Res Bull (1993) 30(3-4):381-386.
14. Canu W, Billiard M, Baldy-Mouliner M: Fasting plasma and CSF amino acid levels in ALS. Acta Neurol Scand (1993) 88(1):51-55.
15. Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA: Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem (2002) 80(4):616-625.
16. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW: Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol (1995) 38(1):73-84.
17. Rothstein JD, Martin LJ, Kuncl RW: Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med (1992) 326(22):1464-1468.
18. Militello A, Vitello G, Lunetta C, Toscano A, Maiorana G, Piccoli T, La Bella V: The serum level of free testosterone is reduced in amyotrophic lateral sclerosis. J Neurol Sci (2002) 195(1):67-70.
19. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW: Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science (1998) 281(5384):1851-1854.
20. Gumey ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX et al: Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (1994) 264(5166):1772-1775.
21. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, Miyamoto N, Showguchi-Miyata J, Okada Y, Singaraja R, Figlewicz DA et al: A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet (2001) 29(2):166-173.
22. Kunst CB, Mezey E, Brownstein MJ, Patterson D: Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions. Nat Genet (1997) 15(1):91-94.
23. Almer G, Vukosavic S, Romero N, Przedborski S: Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem (1999) 72(6):2415-2425.
24. Andersen PM, Nilsson P, Ala-Hurula V, Keranen ML, Tarvainen I, Haltia T, Nilsson L, Binzer M, Forsgren L, Marklund SL: Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet (1995) 10(1):61-66.
25. Jones CT, Swingler RJ, Simpson SA, Brock DJ: Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet (1995) 32(4):290-292.
26. Dal Canto MC, Gurney ME: Neuropathological changes in two lines of mice carrying a transgene for mutant human CuZn SOD, and in mice overexpressing wild type human SOD: A model of familial amyotrophic lateral sclerosis (FALS). Brain Res (1995) 676(1):25-40.
27. Corson LB, Strain JJ, Culotta VC, Cleveland DW: Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc Natl Acad Sci USA (1998) 95(11):6361-6366.
28. Aoki M, Lin CL, Rothstein JD, Geller BA, Hosler BA, Munsat TL, Horvitz HR, Brown RH: Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis. Ann Neurol (1998) 43(5):645-653.
29. Chou SM, Han CY, Wang HS, Vlassara H, Bucala R: A receptor for advanced glycosylation end products (AGEs) is colocalized with neurofilament-bound AGEs and SOD1 in motoneurons of ALS: Immunohistochemical study. J Neurol Sci (1999) 169(1-2):87-92.
30. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson S, Goto J, O'Regan JP, Deng HX et al: Mutations in CuZn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362(6415):59-62.
31. Sasaki S, Warita H, Abe K, Iwata M: Inducible nitric oxide synthase (iNOS) and nitrotyrosine immunoreactivity in the spinal cords of transgenic mice with a G93A mutant SOD1 gene. J Neuropathol Exp Neurol (2001) 60(9):839-846.
32. Shaw CE, Enayat ZE, Chioza BA, Al-Chalabi A, Radunovic A, Powell JF, Leigh PN: Mutations in all five exons of SOD-1 may cause ALS. Ann Neurol (1998) 43(3):390-394.
33. Gong YH, Parsadanian AS, Andreeva A, Snider WD, Elliott JL: Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci (2000) 20(2):660-665.
34. Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA: Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci (2001) 21(10):3369-3374.
35. Lino MM, Schneider C, Caroni P: Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci (2002) 22(12):4825-4832.
36. Kreutzberg GW: Microglia: A sensor for pathological events in the CNS. Trends Neurosci (1996) 19(8):312-318.
37. Hanisch UK: Microglia as a source and target of cytokines. Glia (2002) 40(2):140-155.
38. Streit WJ, Graeber MB, Kreutzberg GW: Functional plasticity of microglia: A review. Glia (1988) 1(5):301-307.
39. Streit WJ, Kreutzberg GW: Response of endogenous glial cells to motor neuron degeneration induced by toxic ricin. J Comp Neurol (1988) 268(2):248-263.
40. Troost D, Van Den Oord JJ, De Jong JM, Swaab DF: Lymphocytic infiltration in the spinal cords of patients with amyotrophic lateral sclerosis. Clin Neuropathol (1989) 8(6):289-294. One of the first studies to identify inflammation in the CNS of patients with ALS, thus identifying a potential therapeutic target.
41. Troost D, Van Den Oord JJ, Vianney De Jong JM: Immunohistochemical characteristics of the inflammatory infiltration in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol (1990) 16(5):401-410.
42. Lampson LA, Kushner PD, Sobel RA: Major histocompatibility complex antigen expression in the affected tissues in amyotrophic-lateral-sclerosis. Ann Neurol (1990) 28(3):365-372. This study, publisher shortly after the initial paper by Troost et al [40], further identifies an inflammatory process occurring in the central nervous system of patients with amyotrophic lateral sclerosis.
43. Kawamata T, Akiyama H, Yamada T, McGeer PL: Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol (1992) 140(3):691-707. This is the third study, published shortly after the initial papers by Troost et al [40] and Lampson et al [41], that confirmed the existence of an inflammatory process occurring in the central nervous system of patients with amyotrophic lateral sclerosis.
44. Banati RB: Visualising microglial activation in vivo. Glia (2002) 40(2):206-217.
45. Banati RB, Gehrmann J, Kellner M, Holsboer F: Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. Clin Neuropathol (1995) 14(4):197-200.
46. Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, Bachetti T: Circulating levels of tumour necrosis factor-α and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett (2000) 287(3):211-214.
47. Obal I, Jakab JS, Siklos L, Engelhardt JI: Recruitment of activated microglia cells in the spinal cord of mice by ALS IgG. Neuroreport (2001) 12(11):2449-2452.
48. Ono S, Hu J, Shimizu N, Imai T, Nakagawa H: Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol Sci (2001) 187(1-2):27-34.
49. Katchar K, Osario L, Conradi S, Wigzell H, Gigliotti D: Disturbances in the peripheral T-cell repertoire of patients with motor neuron disease: High levels of activation and indirect evidence of superantigen. Scand J Immunol (2001) 54(1-2):220-224.
50. Drachman DB, Chaudhry V, Comblath D, Kuncl RW, Pestronk A, Clawson L, Mellits ED, Quaskey S, Quinn T, Calkins A et al: Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol (1994) 35(2):142-150.
51. Haverkamp LJ, Smith RG, Appel SH: Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol (1994) 36(2):253-254.
52. Alexianu ME, Kozovska M, Appel SH: Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology (2001) 57(7):1282-1289.
53. Hall ED, Oostveen JA, Gumey ME: Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia (1998) 23(3):249-256.
54. Elliott JL: Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res (2001) 95(12):172-178.
55. Olsen MK, Roberts SL, Ellerbrock BR, Fleck TJ, McKinley DK, Gumey ME: Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol (2001) 50(6):730-740.
56. Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeguchi H, Doyu M, Sobue G: Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem (2002) 80(1):158-167.
57. Hensley K, Floyd RA, Gordon B, Mou S, Pye QN, Stewart C, West M, Williamson K: Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem (2002) 85(2):365-374.
58. Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L, Kostic V, Przedborski S: Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology (2002) 58(8):1277-1279.
59. Drachman DB, Rothstein JD: Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol (2002) 48(5):792-795.
60. McGeer PL: Cyclooxygenase-2 inhibitors: Rationale and therapeutic potential for Alzheimer's disease. Drugs Aging (2000) 17(1):1-11.
61. Frank KM, Coccia C, Drachman DB, Rothstein JD: COX-2 inhibition prolongs survival in a transgenic mouse model of ALS. Neuroscience (2001) 31 (Part 1):Abs 107.6.
62. Robertson J, Beaulieu JM, Dorouchi MM, Durham HD, Julien JP, Mushynski WE: Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-α. J Cell Biol (2001) 155(2):217-226.
63. He BP, Wen W, Strong MJ: Activated microglia (BV-2) facilitation of TNF-α-mediated motor neuron death in vitro. J Neuroimmunol (2002) 128(1-2):31-38.
64. Raoul C, Estevez AG, Nishmune H, Cleveland PW, DeLapeyriere O, Henderson CE, Haase G, Pettman B: Motoneuron death triggered by a specific pathway downstream of Fas potentiation by ALS-linked SOD1 mutations. Neuron (2002) 35(6):1067-1083.
65. Klegeris A, Walker DG, McGeer PL: Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J Neuroimmunol (1997) 78(1-2):152-161.
66. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J: Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA (1998) 95(26):15769-15774.
67. Yrhanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA (1999) 96(23):13496-13500.
68. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu Du C, Gullans S et al: Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 417(6884):74-78.
69. Kriz J, Nguyen M, Julien J: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2002) 10(3):268.
70. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport (2002) 13(8):1067-1070.
71. Anneser JM, Cookson MR, Ince PG, Shaw PJ, Borasio GD: Glial cells of the spinal cord and subcortical white matter upregulate nitric oxide synthase in sporadic amyotrophic lateral sclerosis. Exp Neurol (2001) 171(2):418-421.
72. Gumey ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED: Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol (1996) 39(2):147-157.
73. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med (1994) 330(9):585-591.
74. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V: Dose-ranging study of riluzole in amyotrophic lateral sclerosis/Riluzole Study Group II. Lancet (1996) 347(9013):1425-1431.
75. Miller RG, Moore D, Young LA, Amon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Mendoza MC, Neville HE, Parry J et al: Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology (1996) 47(6):1383-1388.